<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2023.1213138</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Basophils in pruritic skin diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wiebe</surname>
<given-names>Daniela</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2176235"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Limberg</surname>
<given-names>Maren M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1171383"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gray</surname>
<given-names>Natalie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2327819"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Raap</surname>
<given-names>Ulrike</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/788018"/>
</contrib>
</contrib-group>    <aff id="aff1">
<sup>1</sup>
<institution>Division of Experimental Allergy and Immunodermatology, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg</institution>, <addr-line>Oldenburg</addr-line>, <country>Germany</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Division of Anatomy, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg</institution>, <addr-line>Oldenburg</addr-line>, <country>Germany</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Research Center for Neurosensory Science, Carl von Ossietzky University Oldenburg</institution>, <addr-line>Oldenburg</addr-line>, <country>Germany</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>University Clinic of Dermatology and Allergy, University of Oldenburg</institution>, <addr-line>Oldenburg</addr-line>, <country>Germany</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Christophe Pellefigues, CNRS EMR8252 Centre de Recherche sur l&#x2019;Inflammation, France</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: J&#xf6;rg Scheffel, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Allergology and Immunology, Germany; Mei Li, CNRS UMR7104-INSERM U1258-University of Strasbourg, France</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Ulrike Raap, <email xlink:href="mailto:Raap.Ulrike@klinikum-oldenburg.de">Raap.Ulrike@klinikum-oldenburg.de</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>03</day>
<month>07</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1213138</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>04</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>06</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Wiebe, Limberg, Gray and Raap</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Wiebe, Limberg, Gray and Raap</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Basophils are rare cells in the peripheral blood which have the capability to infiltrate into the skin. Invasion of basophils has been detected in pruritic skin diseases, including atopic dermatitis, bullous pemphigoid, chronic spontaneous urticaria and contact dermatitis. In the skin, basophils are important players of the inflammatory immune response, as they release Th2 cytokines, including interleukin (IL)-4 and IL-13, subsequently inducing the early activation of T-cells. Further, basophils release a multitude of mediators, such as histamine and IL-31, which both play an important role in the initiation of the pruritic response <italic>via</italic> activation of sensory nerves. Chronic pruritus significantly affects the quality of life and the working capability of patients, though its mechanisms are not fully elucidated yet. Since basophils and neurons share many receptors and channels, bidirectional interaction mechanisms, which drive the sensation of itch, are highlighted in this review.</p>
</abstract>
<kwd-group>
<kwd>basophils</kwd>
<kwd>IL-31</kwd>
<kwd>atopic dermatitis</kwd>
<kwd>neuro-immune interaction</kwd>
<kwd>pruritus</kwd>
</kwd-group>
<contract-num rid="cn001">RA 1026/3-2</contract-num>
<contract-num rid="cn002">FP 2020-053</contract-num>
<contract-sponsor id="cn001">Deutsche Forschungsgemeinschaft<named-content content-type="fundref-id">10.13039/501100001659</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Carl von Ossietzky Universit&#xe4;t Oldenburg<named-content content-type="fundref-id">10.13039/100019559</named-content>
</contract-sponsor>
<counts>
<fig-count count="1"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="101"/>
<page-count count="8"/>
<word-count count="4162"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Molecular Innate Immunity</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Basophil granulocytes are named due to their affinity to basic dyes (<xref ref-type="bibr" rid="B1">1</xref>). The diameter of basophils is 10 - 14 &#xb5;m (<xref ref-type="bibr" rid="B2">2</xref>) and basophils are the least abundant type of granulocytes in human blood, where they comprise less than 1% of all leucocytes (<xref ref-type="bibr" rid="B1">1</xref>). After differentiation from hematopoietic stem cells in the bone marrow, fully matured basophils enter the blood stream (<xref ref-type="bibr" rid="B2">2</xref>). Basophils do not proliferate (<xref ref-type="bibr" rid="B3">3</xref>) and have a short lifespan of 60 - 70 h in mice (<xref ref-type="bibr" rid="B4">4</xref>). In humans, lifespans of up to 11 days have been reported (<xref ref-type="bibr" rid="B5">5</xref>). During helminth elimination, basophils are involved in protective mechanisms and also play a significant role in enhancing inflammation (<xref ref-type="bibr" rid="B6">6</xref>). Basophils are an important early source of Th2-type cytokines such as interleukin (IL)-4 and IL-13 in inflammation (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B7">7</xref>). Moreover, basophils release the pruritic cytokine IL-31, and express its receptor complex consisting of the IL-31 receptor A (IL-31RA), and the oncostatin M receptor &#x3b2; (OSMR&#x3b2;) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>, <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B21">21</xref>). Stimulating basophils with IL-31 induces basophil chemotaxis and promotes the secretion of Th2 cytokines (<xref ref-type="bibr" rid="B21">21</xref>). Another itch mediator is histamine. The pruritogen is released after activation of the high-affinity IgE receptor Fc&#x3f5;RI (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B33">33</xref>). A specific characteristic of human basophils is the potentiation of mediator release after stimulation with priming factors. In the pathogenesis of inflammatory diseases, enhancing factors, such as IL-3, nerve growth factor (NGF), IL-5 and granulocyte macrophage-colony stimulating factor (GM-CSF), modulate the functional activity of basophils. IL-3 is the most potent activator of basophils and also promotes basophil differentiation (<xref ref-type="bibr" rid="B35">35</xref>). Its receptor &#x3b1;-chain CD123 is expressed by basophils (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B13">13</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>). Another priming agent for basophils is the neurotrophin NGF, which induces the release of histamine and the synthesis of leukotriene C4 (LTC4) after stimulation with agonists (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B36">36</xref>). NGF has similar effects on basophils as IL-5 and GM-CSF (<xref ref-type="bibr" rid="B36">36</xref>). While IL-5 belongs to the group of Th2 cytokines (<xref ref-type="bibr" rid="B37">37</xref>), GM-CSF is a monomeric glycoprotein that is present at sites of tissue inflammation (<xref ref-type="bibr" rid="B38">38</xref>). Both are produced by basophils and promote inflammation (<xref ref-type="bibr" rid="B39">39</xref>). Activation of basophils is associated with upregulation of the cell surface markers CD13, CD45, CD63, CD203c (<xref ref-type="bibr" rid="B40">40</xref>), and CD69, for which increased expression is mostly observed after stimulation with IL-3 (<xref ref-type="bibr" rid="B41">41</xref>). A method to assess human basophil activation is to determine changes in the amount of these surface proteins. The most reliable activation markers are CD63 and CD203c (<xref ref-type="bibr" rid="B40">40</xref>). CD63 is a membrane protein, that is associated with histamine containing granules. After anaphylactic degranulation (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>), CD63 is translocated to the cell surface of activated basophils as a result of histamine release (<xref ref-type="bibr" rid="B43">43</xref>). The ectoenzyme CD203c (pyrophosphatase/phosphodiesterase) is weakly expressed on resting basophils (<xref ref-type="bibr" rid="B44">44</xref>). Whereas CD63 externalization is closely related to basophil degranulation (<xref ref-type="bibr" rid="B44">44</xref>). Upon activation, CD203c, which is not associated with mediator release, is upregulated rapidly (<xref ref-type="bibr" rid="B43">43</xref>). Basophil infiltration has been observed in atopic dermatitis (AD), bullous pemphigoid (BP), chronic spontaneous urticaria (CSU) and contact dermatitis (<xref ref-type="bibr" rid="B7">7</xref>), all of which are pruritic inflammatory skin diseases. The mechanism how basophils are recruited into the skin remains to be fully elucidated. It is assumed that basophils are attracted by a variety of mediators present in the skin, i.e. the chemokines, CCL2, CCL5, CCL11, CXCL12, and prostaglandin D2 (<xref ref-type="bibr" rid="B45">45</xref>). Basophils express the respective receptors, CCR4 for CCL2 and CCL5, CCR3 for CCL11, CXCR4 for CXCL12 and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) for prostaglandin D2 (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>). CCL11 is produced by dermal fibroblasts and CRTH2 is elevated in AD (<xref ref-type="bibr" rid="B46">46</xref>). Other potential chemoattractants of basophils are thymic stromal lymphopoietin (TSLP), IL-3, IL-31, histamine, substance P (SP) and sphingosine-1-phosphate (S1P). TSLP and IL-3 cause the upregulation of CXCR4 and thereby lead to infiltration of basophils into the skin (<xref ref-type="bibr" rid="B47">47</xref>). The pruritogen IL-31 has been shown to induce chemotaxis in basophils <italic>in vitro</italic> (<xref ref-type="bibr" rid="B21">21</xref>). Upon histamine release from mast cells, murine basophils are recruited to the site of allergen exposure in nasal tissue (<xref ref-type="bibr" rid="B48">48</xref>). SP has also been shown to chemoattract basophils, resulting in the infiltration of basophils into the skin of healthy individuals (<xref ref-type="bibr" rid="B49">49</xref>). Recently, it was shown that in healthy donors, basophils migrate towards S1P which was observed in an <italic>in vitro</italic> study, while in AD patients a chemorepulsive effect was detected (<xref ref-type="bibr" rid="B31">31</xref>). It has however, so far not been described if basophils, that migrated into the skin, return to the blood or travel to draining lymph nodes (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B50">50</xref>). Pruritus elicits the desire to scratch the skin and is categorized into acute and chronic pruritus. Chronic itch, by definition, lasts longer than 6 weeks, and strongly impairs patients&#x2019; quality of life. Although its complete mechanism has yet to be elucidated, complex crosstalk between the stratum corneum, keratinocytes, immune cells, and nerve fibers (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) plays an important role in the initiation and maintenance of pruritus. Itch can originate in the skin or have neuropathic, psychogenic or systemic causes (<xref ref-type="bibr" rid="B51">51</xref>). Histamine, IL-31, SP, LTC4, IL-4, IL-13, NGF, brain-derived neurotrophic factor (BDNF), and TSLP, which all are released by or affect basophils (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>), have been reported to cause itch (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B52">52</xref>&#x2013;<xref ref-type="bibr" rid="B54">54</xref>) and are described in the chapter &#x201c;Basophils and neuro-immune interactions&#x201d;. Current therapies for itch target different receptors on basophils, such as IL-31RA, neurokinin 1 receptor (NK1R), tropomyosin-receptor kinase A (trkA), or released mediators, i.e. IL-13. The monoclonal IL-31RA antibody nemolizumab binds to IL-31RA and thereby interrupts IL-31 itch signaling in basophils. A trial from Japan in which nemolizumab was administered, found improvements in pruritus and quality of life, leading to the approval of the drug for AD (<xref ref-type="bibr" rid="B55">55</xref>). NK1R is expressed in basophils and its antagonists inhibit pruritic signaling and decrease itch in patients. However, the inhibitors are not licensed for use (<xref ref-type="bibr" rid="B56">56</xref>). In mice, treatment with signal transducer and activator of transcription 6 (STAT6) inhibitors led to decreased scratching. IL-13 targets STAT6, inducing pruritus (<xref ref-type="bibr" rid="B57">57</xref>). Janus kinase (JAK) inhibitors interrupt the JAK-STAT signaling pathway. This disruption, which occurs after treatment with JAK inhibitor upadacitinib, leads to improvement of pruritus in patients (<xref ref-type="bibr" rid="B58">58</xref>). Application of the trkA inhibitor CT327 resulted in a significant decrease of pruritus in psoriasis patients (<xref ref-type="bibr" rid="B59">59</xref>). The role of basophils as important effector cells in different inflammatory skin diseases and their involvement in pruritus, are described in the following chapters.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Expression of receptors and release of cytokines in human basophils. Basophils interact with other immune cells and neurons through inflammatory mediators and receptor expressions. Interleukin (IL)-31, as well as its receptor complex consisting of the IL-31 receptor A and the oncostatin M receptor &#x3b2;, are expressed by basophils and contribute to pruritus. Stimulation with IL-31 leads to the secretion of the pro-inflammatory cytokines IL-4 and IL-13. Their respective receptors are IL-4R and IL-13R. Basophils express the high-affinity receptor Fc&#x3f5;RI. Upon crosslinking of the receptor with IgE, histamine is released, mediating itch. The hormone receptors are present on the cell surface, with the histamine 4 receptor being the most highly expressed. Activation of the neurokinin 1 receptor through substance P (SP) also causes histamine release. Basophils can be primed by IL-5, IL-3 and granulocyte macrophage-colony stimulating factor (GM-CSF). The respective receptors are CD125 and CD131 for IL-5, CD123 and CD131 for IL-3 and the GM-CSF receptor consists of GM-CSFR&#x3b1; and GM-CSFR&#x3b2;. Activation of these receptors leads to increased histamine release. Another priming factor is nerve-growth factor, which binds to the tyrosine kinase A receptor on the cell surface. Basophils express the Mas-related G protein-coupled receptor X2 (MRGPRX2), which is part of the signaling cascade in inflammation and serves as a receptor for SP. Another pruritogen is thymic stromal lymphopoietin (TSLP), which binds to the TSLP receptor complex consisting of TSLP receptor and IL-7 receptor &#x3b1; and is proposed to cause itch. Whether basophils respond to TSLP is controversial. The lipid mediator sphingosine-1-phosphate (S1P) is stored in granules and its receptor S1P receptor 1 is expressed on the cell surface. It is proposed to have an anti-inflammatory effect on basophils. The leukotriene C4 (LTC4) is released by basophils and its receptor cysteinyl leukotriene receptor (LTCR) is expressed by basophils. GM-CSF: granulocyte macrophage-colony stimulating factor; GM-CSFR&#x3b1;: GM-CSF receptor &#x3b1;; GM-CSFR&#x3b2;: GM-CSF receptor &#x3b2;; H1/H4: histamine 1/4 receptor; IL: interleukin; IL-4R: IL-4 receptor; IL-5R: IL-5 receptor; IL-7RA: IL-7 receptor &#x3b1;; IL-13R: IL13 receptor; IL-31RA: IL-31 receptor A; LTC4: leukotriene C4; LTCR: cysteinyl leukotriene receptor; MRGPRX2: Mas-related G protein-coupled receptor X2; NK1R: neurokinin 1 receptor; OSMR&#x3b2;: oncostatin M receptor &#x3b2;; trkA: tyrosine kinase receptor A; TSLP: thymic stromal lymphopoietin; TSLPR: TSLP receptor; SP: substance P; S1P: sphingosine-1-phosphate; S1PR1: S1P receptor 1.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1213138-g001.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Shared receptors of basophils and neurons with their respective ligand.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Shared receptor</th>
<th valign="top" align="center">Ligand</th>
<th valign="top" align="center">References</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">GM-CSFR&#x3b1;/&#x3b2;</td>
<td valign="top" align="left">GM-CSF</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">H1/H4</td>
<td valign="top" align="left">Histamine</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IL-4R</td>
<td valign="top" align="left">IL-4</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B12">12</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IL-3R</td>
<td valign="top" align="left">IL-3</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B13">13</xref>&#x2013;<xref ref-type="bibr" rid="B18">18</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IL-5R</td>
<td valign="top" align="left">IL-5</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IL-13R</td>
<td valign="top" align="left">IL-13</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B12">12</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IL-31 receptor complex</td>
<td valign="top" align="left">IL-31</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">LTCR</td>
<td valign="top" align="left">LTC4</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B23">23</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">MRGPRX2</td>
<td valign="top" align="left">SP</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">NK1R</td>
<td valign="top" align="left">SP</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">trkA</td>
<td valign="top" align="left">NGF</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">TSLP receptor complex</td>
<td valign="top" align="left">TSLP</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B30">30</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">S1PR1</td>
<td valign="top" align="left">S1P</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Fc&#x3f5;RI</td>
<td valign="top" align="left">IgE</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>GM-CSF, granulocyte macrophage-colony stimulating factor; GM-CSFR&#x3b1;/&#x3b2;, GM-CSF receptor &#x3b1; and &#x3b2;; H1/H4, histamine 1/4 receptor; IL, interleukin; IL-3R: IL-3 receptor; IL-4R: IL-4 receptor; IL-5R, IL-5 receptor; IL-7RA, IL-7 receptor &#x3b1;; IL-13R, IL13 receptor; IL-31RA, IL-31 receptor A; LTC4, leukotriene C4; LTCR, cysteinyl leukotriene receptor; MRGPRX2, Mas-related G protein-coupled receptor X2; NK1R, neurokinin 1 receptor; OSMR&#x3b2;, oncostatin M receptor &#x3b2;; trkA, tyrosine kinase receptor A; TSLP, thymic stromal lymphopoietin; TSLPR, TSLP receptor; SP, substance P; S1P, sphingosine-1-phosphate; S1PR1, S1P receptor 1.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s2">
<title>Atopic dermatitis</title>
<p>Atopic dermatitis (AD) is an inflammatory skin disease, associated with recurrent dry skin, and the main bothersome symptom, itch (<xref ref-type="bibr" rid="B60">60</xref>). In patients with AD, infiltration of basophils into the skin and peripheral blood has been observed, although not in as high numbers as in other skin diseases (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B61">61</xref>). In one study, significantly less basophil numbers could be detected in peripheral blood of AD patients than in healthy controls (<xref ref-type="bibr" rid="B62">62</xref>). Interestingly, increased basophil count is suggested to be a potential causal risk factor for AD (<xref ref-type="bibr" rid="B63">63</xref>). Basophils were found to exhibit increased externalization of the activation markers CD63 and CD203c in AD patients (<xref ref-type="bibr" rid="B61">61</xref>). This indicates possible involvement of basophils in the pathogenesis of AD. Basophils can be primed by NGF (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>), which is produced by a variety of cells, such as keratinocytes (<xref ref-type="bibr" rid="B53">53</xref>), eosinophils (<xref ref-type="bibr" rid="B64">64</xref>), T cells (<xref ref-type="bibr" rid="B65">65</xref>), and mast cells (<xref ref-type="bibr" rid="B66">66</xref>). NGF has been shown to be either increased (<xref ref-type="bibr" rid="B53">53</xref>), or significantly decreased in AD patients, correlating with disease severity when compared to healthy subjects (<xref ref-type="bibr" rid="B67">67</xref>). In lesional skin of subjects with AD, the number of NGF positive nerve fibers is increased (<xref ref-type="bibr" rid="B68">68</xref>). Whether basophils are a source of NGF, has yet to be elucidated. In the epidermis, the lipid mediator sphingosine-1-phosphate (S1P) plays an important role regarding structure, lipid signaling and the regulation of keratinocytes. Our group recently discovered that isolated basophils of atopic patients exhibited decreased S1PR1 expression, and possessed intracellular S1P in isolated basophils (<xref ref-type="bibr" rid="B31">31</xref>). Furthermore, in the stratum corneum of AD patients, the lipid is decreased, which might alleviate colonization with <italic>Staphylococcus aureus</italic> (<xref ref-type="bibr" rid="B69">69</xref>). The lipid, as well as mRNA expression of the S1P receptors (S1PR) S1PR1, S1PR2, S1PR3 and S1PR4, have been observed in human basophils (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B31">31</xref>). The presence of S1PR1 was also confirmed at the cell surface (<xref ref-type="bibr" rid="B31">31</xref>) (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). S1PR1, S1PR2 and S1PR4 have been detected in the brain (<xref ref-type="bibr" rid="B32">32</xref>), indicating another point of neuro-immune crosstalk. Due to the inhibiting effect of the lipid mediator on chemotaxis, S1P is proposed to have an anti-inflammatory effect on basophils (<xref ref-type="bibr" rid="B31">31</xref>). In both mice and humans, significant upregulation of Fc&#x3f5;RI on basophils during AD has been observed, indicating that IgE might also be an important factor in pruritus (<xref ref-type="bibr" rid="B70">70</xref>). The pro-inflammatory effect of basophils in AD might be reduced by treatment with dupilumab. The monoclonal IgG4 antibody, which binds to IL-4R&#x3b1;, showed success in reducing symptoms, such as itch, of AD patients (<xref ref-type="bibr" rid="B71">71</xref>). Since the antibody binds to IL-4R&#x3b1;, the assumption arises, that the cytokines which contribute to the disease are partially derived from basophils (<xref ref-type="bibr" rid="B71">71</xref>). Aside from their pro-inflammatory properties, basophils can aid in the resolution of AD. The expansion of M2-like macrophages was promoted by murine basophils, as well as epidermal repair (<xref ref-type="bibr" rid="B72">72</xref>), which additionally affirms the role of basophils in AD.</p>
</sec>
<sec id="s3">
<title>Bullous pemphigoid</title>
<p>Bullous pemphigoid (BP) is a blistering skin disease, that most commonly occurs in elderly people and only rarely affects adolescents or children. An autoimmune reaction against the hemidesmosomal proteins BP180 and BP230 leads to the formation of blisters (<xref ref-type="bibr" rid="B73">73</xref>). A case study showed that basophil infiltration took place in early- as well as late-stage lesions (<xref ref-type="bibr" rid="B74">74</xref>). The twofold involvement of basophils in BP was shown by Kimura et&#xa0;al. (<xref ref-type="bibr" rid="B75">75</xref>). During the early stage of BP, basophil infiltration was correlated with eosinophil infiltration. Cell-to-cell contact was observed, indicating that Th2 immunity is promoted by eosinophils and basophils (<xref ref-type="bibr" rid="B75">75</xref>). A case study detected the colocalization of basophils and eosinophils in urticarial plaques (<xref ref-type="bibr" rid="B74">74</xref>). The presence of basophils was also demonstrated, as well as eosinophils, underneath the subepidermal cleft during the late-stage of BP (<xref ref-type="bibr" rid="B74">74</xref>). Basophils in BP were shown to be present with a high density, similar to that observed in urticaria, but higher than that in AD (<xref ref-type="bibr" rid="B46">46</xref>), and increased compared to skin healthy controls (<xref ref-type="bibr" rid="B76">76</xref>). Circulating basophils from untreated BP patients were stimulated with BP180, resulting in significantly higher histamine release than those basophils of treated BP patients or healthy controls (<xref ref-type="bibr" rid="B77">77</xref>). This suggests an important role for basophils in the development of BP. The amount of anti-basement membrane zone antibodies was positively correlated with IgE serum levels (<xref ref-type="bibr" rid="B78">78</xref>). Treatment with the anti-IgE monoclonal antibody omalizumab resulted in the downregulation of Fc&#x3f5;RI on basophils in two cases (<xref ref-type="bibr" rid="B79">79</xref>). Activation of basophils was determined through measuring CD203c expression. The expression was evaluated before and after treatment with two doses of prednisolone and three sessions of plasma exchange, and found to be significantly reduced after treatment (<xref ref-type="bibr" rid="B74">74</xref>). These observations indicate that basophils play a role in the development of BP. In BP, itch is an important factor, which is confirmed as itch severity correlates with the increased numbers of basophils present in the blisters (<xref ref-type="bibr" rid="B76">76</xref>). Thus, basophils seem to play an important role in pruritus, blister development and inflammation in BP.</p>
</sec>
<sec id="s4">
<title>Chronic spontaneous urticaria</title>
<p>Chronic spontaneous urticaria (CSU) presents in patients as pruritic hives, angioedema or a combination of both (<xref ref-type="bibr" rid="B80">80</xref>). Patients suffering from CSU often present with peripheral basopenia, where low amounts of basophils are present in the blood, probably due to the infiltration into the skin (<xref ref-type="bibr" rid="B81">81</xref>). An inverse correlation between disease severity and the amount of basophils in the blood has been observed (<xref ref-type="bibr" rid="B81">81</xref>). Moreover, significantly more infiltrating basophils are present in lesions of CSU patients than in nonatopic subjects (<xref ref-type="bibr" rid="B82">82</xref>). Basophil degranulation has also been observed in the skin of CSU patients. Therefore, the reactivity in CSU seems to be partially regulated by basophils (<xref ref-type="bibr" rid="B82">82</xref>). Substance P (SP) was shown to be positively correlated with the number of basophils in the peripheral blood of CSU patients (<xref ref-type="bibr" rid="B26">26</xref>). Interestingly, basophil numbers were increased in CSU patients compared to healthy controls, in contrast to findings of other studies. These basophils exhibited higher expression levels of SP, as well as its associated receptor NK1R, than those from healthy controls. When activated by its agonist, NK1R mediated up to 41% net histamine release, which is comparable to that induced by anti-IgE and the chemoattractant N-formylmethionyl-leucyl-phenylalanine (fMLP) (<xref ref-type="bibr" rid="B26">26</xref>). A similar effect was confirmed in mice. Blood basophil numbers increased after injection with SP. Sensitization with ovalbumin resulted in elevated basophils numbers as well as increased SP and NK1R expression on basophils (<xref ref-type="bibr" rid="B26">26</xref>). As itch is a significant symptom of CSU, its origin is important. One causative factor might be IL-31, which is elevated in this disease (<xref ref-type="bibr" rid="B83">83</xref>). Basophils have been reported to be the main source of IL-31 in skin lesions of CSU (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B21">21</xref>). In CSU, patients can be categorized in three groups; responders, nonresponders and basopenics, depending on how much histamine is released from basophils after stimulation with anti-IgE (<xref ref-type="bibr" rid="B84">84</xref>). Upon application of anti-IgE, basophils of responders release high amounts of histamine and exhibit increased CD63 externalization. Nonresponders are characterized by low histamine secretion and CD63 externalization, while almost no reaction can be observed in basophils of basopenics (<xref ref-type="bibr" rid="B84">84</xref>). Responders, those with high histamine release, seem to suffer from CSU longer than the other groups. However, the number and size of hives, as well as the itch score were highest in basopenics (<xref ref-type="bibr" rid="B84">84</xref>). Another study confirmed that the duration of the disease is longer in responders. The same group of patients also reported increased itch (<xref ref-type="bibr" rid="B85">85</xref>). Treatment with the anti-IgE monoclonal antibody omalizumab showed a decrease of symptoms in CSU patients (<xref ref-type="bibr" rid="B86">86</xref>). Furthermore, the number of peripheral blood basophils increased as a result of treatment with omalizumab (<xref ref-type="bibr" rid="B87">87</xref>). Whether the monoclonal antibody inhibits basophil migration into the skin, or promotes the release of new basophils from the bone marrow has yet to be investigated. Basophils of CSU patients exhibited significantly higher amounts of CD63, than those of healthy controls. CD203c expression however was unchanged (<xref ref-type="bibr" rid="B88">88</xref>). In contrast, another study revealed no difference of activation marker levels in CSU patients in comparison with healthy subjects. However, histamine release was reported to be higher in patients with CSU than in controls (<xref ref-type="bibr" rid="B89">89</xref>). In CSU patients in remission, basophils were more activated, as determined through the presence of CD63 and CD203c, than in healthy control (<xref ref-type="bibr" rid="B90">90</xref>). This shows that basophils are crucial in the development of CSU.</p>
</sec>
<sec id="s5">
<title>Contact dermatitis</title>
<p>Irritant contact dermatitis is characterized by non-allergic, pruritic skin inflammation, where basophils infiltrate into the tissue (<xref ref-type="bibr" rid="B91">91</xref>). In human and murine irritant contact dermatitis skin lesions, basophils were located in proximity to eosinophils, which were recruited to the site by the basophils (<xref ref-type="bibr" rid="B91">91</xref>). Furthermore, in mice, direct cell-to-cell contact of basophils with eosinophils seems to lead to the activation of eosinophils, enhancing the development of irritant contact dermatitis (<xref ref-type="bibr" rid="B91">91</xref>). Allergic contact dermatitis, however, is caused by contact with an allergen, which also induces basophil migration. Interestingly, infiltration lasts for several days, where basophils can be detected after 25 hours and then increase in number in allergic contact dermatitis (<xref ref-type="bibr" rid="B92">92</xref>). Basophils represent 16% of the infiltrate in allergic contact dermatitis at day 16, resulting in delayed hypersensitivity (<xref ref-type="bibr" rid="B92">92</xref>). In accordance with this finding, degranulation of basophils was observed to occur over 72 hours, where approx. 60% of granules were found to be at least partially depleted (<xref ref-type="bibr" rid="B93">93</xref>). Eosinophil infiltration occurs after basophil infiltration, indicating that basophils play a role in eosinophil recruitment in contact dermatitis (<xref ref-type="bibr" rid="B92">92</xref>). Thus, basophils play an important role in the aspects of cell infiltration and pruritus during the development of irritant and allergic contact dermatitis.</p>
</sec>
<sec id="s6">
<title>Basophils and neuro-immune interaction</title>
<p>Interactions between the immune system and the nervous system play an important role in inflammatory skin diseases and pruritus. These neuro-immune interactions stem from intense crosstalk between neurons and immune cells, which are located in close proximity to one another. Upon allergen challenge with the irritant calcipotriol and the allergen ovalbumin, murine basophils migrate into the skin, and are consistently observed to be located in close proximity to sensory nerve fibers (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>), indicating neuroimmune interactions (<xref ref-type="bibr" rid="B70">70</xref>). The initiation and maintenance of itch is characterized by many mediators expressed by basophils, including IL-31, SP, LTC4, histamine, IL-4 and IL-13. Other pruritic mediators, such as TSLP, NGF and BDNF also affect basophils. It is assumed, that basophils interact bidirectionally with neurons through cytokines and neurotrophins, as they share various channels and surface receptors (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>, <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). While IL-31RA is present on most basophils, OSMR&#x3b2; can only be found on a small subpopulation (<xref ref-type="bibr" rid="B21">21</xref>). IL-31RA is expressed on half of dorsal root ganglia (DRG) with a size up to 30 &#xb5;M (<xref ref-type="bibr" rid="B22">22</xref>), and its ligand can act as a neurotrophin on DRG neurons (<xref ref-type="bibr" rid="B94">94</xref>). Through activation of IL-31RA (<xref ref-type="bibr" rid="B22">22</xref>) on peripheral nerves, itch signals are transmitted to the central nervous system (<xref ref-type="bibr" rid="B21">21</xref>).</p>
<p>The Mas-related G-protein-coupled receptor (MRGPR) X2 is expressed on human basophils (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>, <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B24">24</xref>) and DRG (<xref ref-type="bibr" rid="B25">25</xref>), and evokes allergic, as well as nonallergic hypersensitivity (<xref ref-type="bibr" rid="B32">32</xref>). In mice, the transient receptor potential ankyrin 1 (TRPA1) channel is necessary for MRGPR- and TSLP-mediated pruritus (<xref ref-type="bibr" rid="B95">95</xref>). Upon activation, the channel is opened and induces itch (<xref ref-type="bibr" rid="B95">95</xref>).</p>
<p>Basophils release the inflammatory mediator LTC4. Its receptor cysteinyl leukotriene receptor 2 (CysLTR2) is expressed on basophils and DRG (<xref ref-type="bibr" rid="B23">23</xref>).</p>
<p>After priming with IL-3, human basophils express the TSLP receptor, while expression of the IL-7 receptor &#x3b1; was not detectable (<xref ref-type="bibr" rid="B96">96</xref>). In contrast, mice express TSLPR and IL-7 receptor &#x3b1; on basophils (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>), which together form the TSLP receptor complex (<xref ref-type="bibr" rid="B30">30</xref>). Stimulation of basophils with TSLP has been shown to cause histamine release, and increase intracellular IL-4 and IL-13 expression, as well as induce the upregulation of TSLPR in patients with allergic asthma (<xref ref-type="bibr" rid="B97">97</xref>). In contrast to this study, Guen et&#xa0;al. reported that basophils from healthy and allergic patients did not respond to TSLP (<xref ref-type="bibr" rid="B98">98</xref>). The TSLP receptor complex has also been confirmed in DRG. Observations in mice revealed TSLP secretion from basophils and activation of neurons through the cytokine (<xref ref-type="bibr" rid="B12">12</xref>). TSLP activates TRPA1 expressing neurons and causes itch (<xref ref-type="bibr" rid="B99">99</xref>). Secretion of TSLP by human basophils has not yet been investigated.</p>
<p>Basophils and peripheral nerve endings express the tachykinin neurotransmitter SP and its receptor NK1R (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). The neuropeptide is involved in inflammation and itch (<xref ref-type="bibr" rid="B12">12</xref>). Furthermore, SP induces histamine release from basophils, indicating possible interactions between the nervous system and the granulocytes (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>), as basophils are able to communicate with neurons <italic>via</italic> histamine. Basophils express the histamine-1 receptor and histamine-4 receptor (H4R; <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B10">10</xref>), which have also been confirmed to be expressed in the central nervous system (<xref ref-type="bibr" rid="B11">11</xref>). When H4R is activated on basophils, it mediates chemotaxis. However, activation can also lead to basophil silencing, as CD63 and CD203c surface content has been observed to be suppressed and the production and release of sulfidoleukotrienes reduced (<xref ref-type="bibr" rid="B10">10</xref>). In mice, knockout of H4R resulted in reduced inflammation and treatment with H4R antagonists alleviated itch (<xref ref-type="bibr" rid="B12">12</xref>).</p>
<p>Secretion of IL-4 and IL-13 from basophils (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>), indicates communication between basophils and neurons in pruritus. Their respective receptor subunits IL-4R&#x3b1; and IL-13R&#x3b1; are expressed in basophils, as well as in DRG (<xref ref-type="bibr" rid="B12">12</xref>). In a murine model, injection of IL-4 caused scratching, suggesting that IL-4 induces pruritus in mice (<xref ref-type="bibr" rid="B12">12</xref>).</p>
<p>Neurotrophins play an important role in the communication between basophils and neurons. Basophils and the central nervous system express tyrosine kinase receptor A (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B100">100</xref>, <xref ref-type="bibr" rid="B101">101</xref>), to which NGF binds. NGF is also a priming factor for basophils, demonstrating the influence of the neuronal system on basophils. To conclude, interaction between basophils and the neuro-immune system occurs through a variety of channels and mediators, highlighting the importance of basophils in neuro-immune interaction mechanisms.</p>
</sec>
<sec id="s7" sec-type="conclusions">
<title>Conclusion</title>
<p>Basophils play a crucial role in many pruritic inflammatory skin diseases. In these conditions, basophils are among the first cells to infiltrate into the skin. At this location, basophils secrete Th2 cytokines and are drivers of the inflammation. The pruritic effect is further mediated by IL-4, IL-13, IL-31, histamine, SP, TSLP, BDNF and NGF, of which most are released by basophils. IL-31 is a key mediator in itch, its expression being increased in inflammatory and pruritic skin diseases. Basophils also recruit eosinophils to sites of inflammation in BP and CSU, further increasing the inflammation. Moreover, basophils are able to establish cell-to-cell contact with sensory neurons, and enable neuro-immune interaction through the release of inflammatory mediators, such as IL-31. Thus, basophils seem to be major drivers of inflammation and itch in diseases such as AD, BP, CSU and contact dermatitis, which was summarized in this review.</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>Conceptualization, DW and UR. Writing&#x2014;original draft preparation, DW. Writing&#x2014;review and editing, ML, NG, UR. Illustration, ML. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>This work was kindly supported through funds provided by the German Research Foundation RU2690 PruSearch with a grant to Ulrike Raap, grant number RA 1026/3-2, and intramural research funding of the Carl von Ossietzky Universit&#xe4;t Oldenburg, grant numbers FP 2020-053 and FP 2019-033.</p>
</sec>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ehrlich</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Beitr&#xe4;ge zur kenntnis der granulirten bindegewebszellen und der eosinophilen leukoythen</article-title>. <source>Arch Anat Physiol (Leizig)</source> (<year>1879</year>) <volume>3</volume>:<fpage>166</fpage>.</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arock</surname> <given-names>M</given-names>
</name>
<name>
<surname>Schneider</surname> <given-names>E</given-names>
</name>
<name>
<surname>Boissan</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tricottet</surname> <given-names>V</given-names>
</name>
<name>
<surname>Dy</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Differentiation of human basophils: an overview of recent advances and pending questions</article-title>. <source>J Leukocyte Bio</source> (<year>2002</year>) <volume>71</volume>:<page-range>557&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1189/jlb.71.4.557</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karasuyama</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mukai</surname> <given-names>K</given-names>
</name>
<name>
<surname>Obata</surname> <given-names>K</given-names>
</name>
<name>
<surname>Tsujimura</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wada</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Nonredundant roles of basophils in immunity</article-title>. <source>Annu Rev Immunol</source> (<year>2011</year>) <volume>29</volume>:<fpage>45</fpage>&#x2013;<lpage>69</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-031210-101257</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siracusa</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Comeau</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Artis</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>New insights into basophil biology: initiators, regulators, and effectors of type 2 inflammation</article-title>. <source>Ann N Y Acad Sci</source> (<year>2011</year>) <volume>1217</volume>:<page-range>166&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05918.x</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamaguchi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hirai</surname> <given-names>K</given-names>
</name>
<name>
<surname>Morita</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Takaishi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Ohta</surname> <given-names>K</given-names>
</name>
<name>
<surname>Suzuki</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Hemopoietic growth factors regulate the survival of human basophils <italic>in vitro</italic>
</article-title>. <source>Int Arch Allergy Immunol</source> (<year>1992</year>) <volume>97</volume>:<page-range>322&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000236140</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Siracusa</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Basophils in antihelminth immunity</article-title>. <source>Semin Immunol</source> (<year>2021</year>) <volume>53</volume>:<elocation-id>101529</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.smim.2021.101529</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borriello</surname> <given-names>F</given-names>
</name>
<name>
<surname>Granata</surname> <given-names>F</given-names>
</name>
<name>
<surname>Marone</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Basophils and skin disorders</article-title>. <source>J Invest Dermatol</source> (<year>2014</year>) <volume>134</volume>:<page-range>1202&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/jid.2014.16</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voehringer</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Basophil modulation by cytokine instruction</article-title>. <source>Eur J Immunol</source> (<year>2012</year>) <volume>42</volume>:<page-range>2544&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/eji.201142318</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donatien</surname> <given-names>P</given-names>
</name>
<name>
<surname>Anand</surname> <given-names>U</given-names>
</name>
<name>
<surname>Yiangou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sinisi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fox</surname> <given-names>M</given-names>
</name>
<name>
<surname>MacQuillan</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Granulocyte-macrophage colony-stimulating factor receptor expression in clinical pain disorder tissues and role in neuronal sensitization</article-title>. <source>Pain Rep</source> (<year>2018</year>) <volume>3</volume>:<fpage>e676</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/PR9.0000000000000676</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mommert</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kleiner</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gehring</surname> <given-names>M</given-names>
</name>
<name>
<surname>Eiz-Vesper</surname> <given-names>B</given-names>
</name>
<name>
<surname>Stark</surname> <given-names>H</given-names>
</name>
<name>
<surname>Gutzmer</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Human basophil chemotaxis and activation are regulated <italic>via</italic> the histamine H4 receptor</article-title>. <source>Allergy</source> (<year>2016</year>) <volume>71</volume>:<page-range>1264&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/all.12875</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Connelly</surname> <given-names>WM</given-names>
</name>
<name>
<surname>Shenton</surname> <given-names>FC</given-names>
</name>
<name>
<surname>Lethbridge</surname> <given-names>N</given-names>
</name>
<name>
<surname>Leurs</surname> <given-names>R</given-names>
</name>
<name>
<surname>Waldvogel</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Faull</surname> <given-names>RL</given-names>
</name>
<etal/>
</person-group>. <article-title>The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS</article-title>. <source>Br J Pharmacol</source> (<year>2009</year>) <volume>157</volume>:<fpage>55</fpage>&#x2013;<lpage>63</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00227.x</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakashima</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ishida</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kitoh</surname> <given-names>A</given-names>
</name>
<name>
<surname>Otsuka</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kabashima</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus</article-title>. <source>Exp Dermatol</source> (<year>2019</year>) <volume>28</volume>:<page-range>1405&#x2013;11</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/exd.14014</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirai</surname> <given-names>K</given-names>
</name>
<name>
<surname>Morita</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Misaki</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ohta</surname> <given-names>K</given-names>
</name>
<name>
<surname>Takaishi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Suzuki</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Modulation of human basophil histamine release by hemopoietic growth factors</article-title>. <source>J Immunol</source> (<year>1988</year>) <volume>141</volume>:<page-range>3958&#x2013;64</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.141.11.3958</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurimoto</surname> <given-names>Y</given-names>
</name>
<name>
<surname>de Weck</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Dahinden</surname> <given-names>CA</given-names>
</name>
</person-group>. <article-title>Interleukin 3-dependent mediator release in basophils triggered by C5a</article-title>. <source>J Exp Med</source> (<year>1989</year>) <volume>170</volume>:<page-range>467&#x2013;79</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.170.2.467</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schleimer</surname> <given-names>RP</given-names>
</name>
<name>
<surname>Derse</surname> <given-names>CP</given-names>
</name>
<name>
<surname>Friedman</surname> <given-names>B</given-names>
</name>
<name>
<surname>Gillis</surname> <given-names>S</given-names>
</name>
<name>
<surname>Plaut</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lichtenstein</surname> <given-names>LM</given-names>
</name>
<etal/>
</person-group>. <article-title>Regulation of human basophil mediator release by cytokines. i. interaction with antiinflammatory steroids</article-title>. <source>J Immunol</source> (<year>1989</year>) <volume>143</volume>:<page-range>1310&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.143.4.1310</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valent</surname> <given-names>P</given-names>
</name>
<name>
<surname>Besemer</surname> <given-names>J</given-names>
</name>
<name>
<surname>Muhm</surname> <given-names>M</given-names>
</name>
<name>
<surname>Majdic</surname> <given-names>O</given-names>
</name>
<name>
<surname>Lechner</surname> <given-names>K</given-names>
</name>
<name>
<surname>Bettelheim</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Interleukin 3 activates human blood basophils <italic>via</italic> high-affinity binding sites</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>1989</year>) <volume>86</volume>:<page-range>5542&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.86.14.5542</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schroeder</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Chichester</surname> <given-names>KL</given-names>
</name>
<name>
<surname>Bieneman</surname> <given-names>AP</given-names>
</name>
</person-group>. <article-title>Human basophils secrete IL-3: evidence of autocrine priming for phenotypic and functional responses in allergic disease</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>182</volume>:<page-range>2432&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.0801782</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tabira</surname> <given-names>T</given-names>
</name>
<name>
<surname>Chui</surname> <given-names>DH</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Shirabe</surname> <given-names>T</given-names>
</name>
<name>
<surname>Konishi</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Interleukin-3 and interleukin-3 receptors in the brain</article-title>. <source>Ann N Y Acad Sci</source> (<year>1998</year>) <volume>840</volume>:<page-range>107&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1749-6632.1998.tb09554.x</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamada</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zeibecoglou</surname> <given-names>K</given-names>
</name>
<name>
<surname>Bungre</surname> <given-names>J</given-names>
</name>
<name>
<surname>North</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kay</surname> <given-names>AB</given-names>
</name>
<etal/>
</person-group>. <article-title>IL-3, IL-5, granulocyte-macrophage colony-stimulating factor receptor alpha-subunit, and common beta-subunit expression by peripheral leukocytes and blood dendritic cells</article-title>. <source>J Allergy Clin Immunol</source> (<year>1998</year>) <volume>101</volume>:<page-range>677&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0091-6749(98)70177-0</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinho-Ribeiro</surname> <given-names>FA</given-names>
</name>
<name>
<surname>Verri</surname> <given-names>WA</given-names>
</name>
<name>
<surname>Chiu</surname> <given-names>IM</given-names>
</name>
</person-group>. <article-title>Nociceptor sensory neuron-immune interactions in pain and inflammation</article-title>. <source>Trends Immunol</source> (<year>2017</year>) <volume>38</volume>:<fpage>5</fpage>&#x2013;<lpage>19</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.it.2016.10.001</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raap</surname> <given-names>U</given-names>
</name>
<name>
<surname>Gehring</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kleiner</surname> <given-names>S</given-names>
</name>
<name>
<surname>R&#xfc;drich</surname> <given-names>U</given-names>
</name>
<name>
<surname>Eiz-Vesper</surname> <given-names>B</given-names>
</name>
<name>
<surname>Haas</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Human basophils are a source of - and are differentially activated by - IL-31</article-title>. <source>Clin Exp Allergy</source> (<year>2017</year>) <volume>47</volume>:<fpage>499</fpage>&#x2013;<lpage>508</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/cea.12875</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cevikbas</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Akiyama</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kempkes</surname> <given-names>C</given-names>
</name>
<name>
<surname>Savinko</surname> <given-names>T</given-names>
</name>
<name>
<surname>Antal</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1</article-title>. <source>J Allergy Clin Immunol</source> (<year>2014</year>) <volume>133</volume>:<page-range>448&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2013.10.048</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasaki</surname> <given-names>F</given-names>
</name>
<name>
<surname>Yokomizo</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>The leukotriene receptors as therapeutic targets of inflammatory diseases</article-title>. <source>Int Immunol</source> (<year>2019</year>) <volume>31</volume>:<page-range>607&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/intimm/dxz044</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wedi</surname> <given-names>B</given-names>
</name>
<name>
<surname>Gehring</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kapp</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>The pseudoallergen receptor MRGPRX2 on peripheral blood basophils and eosinophils: expression and function</article-title>. <source>Allergy</source> (<year>2020</year>) <volume>75</volume>:<page-range>2229&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/all.14213</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robas</surname> <given-names>N</given-names>
</name>
<name>
<surname>Mead</surname> <given-names>E</given-names>
</name>
<name>
<surname>Fidock</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion</article-title>. <source>J Biol Chem</source> (<year>2003</year>) <volume>278</volume>:<page-range>44400&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M302456200</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>C</given-names>
</name>
<name>
<surname>He</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Upregulated expression of substance p in basophils of the patients with chronic spontaneous urticaria: induction of histamine release and basophil accumulation by substance p</article-title>. <source>Cell Biol Toxicol</source> (<year>2016</year>) <volume>32</volume>:<page-range>217&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10565-016-9330-4</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinhoff</surname> <given-names>M</given-names>
</name>
<name>
<surname>Buddenkotte</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lerner</surname> <given-names>EA</given-names>
</name>
</person-group>. <article-title>Role of mast cells and basophils in pruritus</article-title>. <source>Immunol Rev</source> (<year>2018</year>) <volume>282</volume>:<page-range>248&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/imr.12635</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poto</surname> <given-names>R</given-names>
</name>
<name>
<surname>Gambardella</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Marone</surname> <given-names>G</given-names>
</name>
<name>
<surname>Schroeder</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Mattei</surname> <given-names>F</given-names>
</name>
<name>
<surname>Schiavoni</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Basophils from allergy to cancer</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>1056838</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1056838</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Djouhri</surname> <given-names>L</given-names>
</name>
<name>
<surname>McMullan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Berry</surname> <given-names>C</given-names>
</name>
<name>
<surname>Okuse</surname> <given-names>K</given-names>
</name>
<name>
<surname>Waxman</surname> <given-names>SG</given-names>
</name>
<etal/>
</person-group>. <article-title>trkA is expressed in nociceptive neurons and influences electrophysiological properties <italic>via</italic> Nav1.8 expression in rapidly conducting nociceptors</article-title>. <source>J Neurosci</source> (<year>2005</year>) <volume>25</volume>:<page-range>4868&#x2013;78</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0249-05.2005</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varricchi</surname> <given-names>G</given-names>
</name>
<name>
<surname>Raap</surname> <given-names>U</given-names>
</name>
<name>
<surname>Rivellese</surname> <given-names>F</given-names>
</name>
<name>
<surname>Marone</surname> <given-names>G</given-names>
</name>
<name>
<surname>Gibbs</surname> <given-names>BF</given-names>
</name>
</person-group>. <article-title>Human mast cells and basophils-how are they similar how are they different</article-title>? <source>Immunol Rev</source> (<year>2018</year>) <volume>282</volume>:<fpage>8</fpage>&#x2013;<lpage>34</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/imr.12627</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gray</surname> <given-names>N</given-names>
</name>
<name>
<surname>Limberg</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Wiebe</surname> <given-names>D</given-names>
</name>
<name>
<surname>Weihrauch</surname> <given-names>T</given-names>
</name>
<name>
<surname>Langner</surname> <given-names>A</given-names>
</name>
<name>
<surname>Brandt</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Differential upregulation and functional activity of S1PR1 in human peripheral blood basophils of atopic patients</article-title>. <source>Int J Mol Sci</source> (<year>2022</year>) <volume>23</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms232416117</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aarthi</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Darendeliler</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Pushparaj</surname> <given-names>PN</given-names>
</name>
</person-group>. <article-title>Dissecting the role of the S1P/S1PR axis in health and disease</article-title>. <source>J Dent Res</source> (<year>2011</year>) <volume>90</volume>:<page-range>841&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/0022034510389178</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galli</surname> <given-names>SJ</given-names>
</name>
</person-group>. <article-title>Mast cells and basophils</article-title>. <source>Curr Opin Hematol</source> (<year>2000</year>) <volume>7</volume>:<page-range>32&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/00062752-200001000-00007</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Kleij</surname> <given-names>H</given-names>
</name>
<name>
<surname>Charles</surname> <given-names>N</given-names>
</name>
<name>
<surname>Karimi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>Y-K</given-names>
</name>
<name>
<surname>Foster</surname> <given-names>J</given-names>
</name>
<name>
<surname>Janssen</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Evidence for neuronal expression of functional fc (epsilon and gamma) receptors</article-title>. <source>J Allergy Clin Immunol</source> (<year>2010</year>) <volume>125</volume>:<page-range>757&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2009.10.054</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valent</surname> <given-names>P</given-names>
</name>
<name>
<surname>Schmidt</surname> <given-names>G</given-names>
</name>
<name>
<surname>Besemer</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mayer</surname> <given-names>P</given-names>
</name>
<name>
<surname>Zenke</surname> <given-names>G</given-names>
</name>
<name>
<surname>Liehl</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Interleukin-3 is a differentiation factor for human basophils</article-title>. <source>Blood</source> (<year>1989</year>) <volume>73</volume>:<page-range>1763&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.V73.7.1763.1763</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bischoff</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Dahinden</surname> <given-names>CA</given-names>
</name>
</person-group>. <article-title>Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils</article-title>. <source>Blood</source> (<year>1992</year>) <volume>79</volume>:<page-range>2662&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.V79.10.2662.bloodjournal79102662</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gieseck</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Wynn</surname> <given-names>TA</given-names>
</name>
</person-group>. <article-title>Type 2 immunity in tissue repair and fibrosis</article-title>. <source>Nat Rev Immunol</source> (<year>2018</year>) <volume>18</volume>:<fpage>62</fpage>&#x2013;<lpage>76</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri.2017.90</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becher</surname> <given-names>B</given-names>
</name>
<name>
<surname>Tugues</surname> <given-names>S</given-names>
</name>
<name>
<surname>Greter</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>GM-CSF: from growth factor to central mediator of tissue inflammation</article-title>. <source>Immunity</source> (<year>2016</year>) <volume>45</volume>:<page-range>963&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2016.10.026</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>L</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhen</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Interleukin 2 regulates the activation of human basophils</article-title>. <source>Cytokine</source> (<year>2020</year>) <volume>127</volume>:<elocation-id>154934</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cyto.2019.154934</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chirumbolo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Vella</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ortolani</surname> <given-names>R</given-names>
</name>
<name>
<surname>de Gironcoli</surname> <given-names>M</given-names>
</name>
<name>
<surname>Solero</surname> <given-names>P</given-names>
</name>
<name>
<surname>Tridente</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Differential response of human basophil activation markers: a multi-parameter flow cytometry approach</article-title>. <source>Clin Mol Allergy</source> (<year>2008</year>) <volume>6</volume>:<elocation-id>12</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1476-7961-6-12</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshimura</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yamaguchi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Iikura</surname> <given-names>M</given-names>
</name>
<name>
<surname>Izumi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kudo</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nagase</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Activation markers of human basophils: CD69 expression is strongly and preferentially induced by IL-3</article-title>. <source>J Allergy Clin Immunol</source> (<year>2002</year>) <volume>109</volume>:<page-range>817&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1067/mai.2002.123532</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Dvorak</surname> <given-names>AM</given-names>
</name>
</person-group>. <article-title>Degranulation of basophils and mast cells</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Dvorak</surname> <given-names>AM</given-names>
</name>
</person-group>, editor. <source>Editor. basophil and mast cell degranulation and recovery</source>. <publisher-loc>Boston, MA: Springer US</publisher-loc>: <publisher-name>Imprint; Springer</publisher-name> (<year>1991</year>). p. <fpage>101</fpage>&#x2013;<lpage>275</lpage>.</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boumiza</surname> <given-names>R</given-names>
</name>
<name>
<surname>Debard</surname> <given-names>A-L</given-names>
</name>
<name>
<surname>Monneret</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>The basophil activation test by flow cytometry: recent developments in clinical studies, standardization and emerging perspectives</article-title>. <source>Clin Mol Allergy</source> (<year>2005</year>) <volume>3</volume>:<elocation-id>9</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1476-7961-3-9</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hauswirth</surname> <given-names>AW</given-names>
</name>
<name>
<surname>Natter</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ghannadan</surname> <given-names>M</given-names>
</name>
<name>
<surname>Majlesi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Schernthaner</surname> <given-names>G-H</given-names>
</name>
<name>
<surname>Sperr</surname> <given-names>WR</given-names>
</name>
<etal/>
</person-group>. <article-title>Recombinant allergens promote expression of CD203c on basophils in sensitized individuals</article-title>. <source>J Allergy Clin Immunol</source> (<year>2002</year>) <volume>110</volume>:<page-range>102&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1067/mai.2002.125257</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shibuya</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>BS</given-names>
</name>
</person-group>. <article-title>Skin-homing basophils and beyond</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>1059098</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1059098</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ito</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Satoh</surname> <given-names>T</given-names>
</name>
<name>
<surname>Takayama</surname> <given-names>K</given-names>
</name>
<name>
<surname>Miyagishi</surname> <given-names>C</given-names>
</name>
<name>
<surname>Walls</surname> <given-names>AF</given-names>
</name>
<name>
<surname>Yokozeki</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Basophil recruitment and activation in inflammatory skin diseases</article-title>. <source>Allergy</source> (<year>2011</year>) <volume>66</volume>:<page-range>1107&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1398-9995.2011.02570.x</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayes</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Ward</surname> <given-names>S</given-names>
</name>
<name>
<surname>Crawford</surname> <given-names>G</given-names>
</name>
<name>
<surname>Seoane</surname> <given-names>RC</given-names>
</name>
<name>
<surname>Jackson</surname> <given-names>WD</given-names>
</name>
<name>
<surname>Kipling</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammation-induced IgE promotes epithelial hyperplasia and tumour growth</article-title>. <source>eLife</source> (<year>2020</year>) <volume>9</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.7554/eLife.51862</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyake</surname> <given-names>K</given-names>
</name>
<name>
<surname>Karasuyama</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Emerging roles of basophils in allergic inflammation</article-title>. <source>Allergol Int</source> (<year>2017</year>) <volume>66</volume>:<page-range>382&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.alit.2017.04.007</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cima</surname> <given-names>K</given-names>
</name>
<name>
<surname>Vogelsinger</surname> <given-names>H</given-names>
</name>
<name>
<surname>K&#xe4;hler</surname> <given-names>CM</given-names>
</name>
</person-group>. <article-title>Sensory neuropeptides are potent chemoattractants for human basophils <italic>in vitro</italic>
</article-title>. <source>Regul Pept</source> (<year>2010</year>) <volume>160</volume>:<page-range>42&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.regpep.2009.12.013</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sokol</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Medzhitov</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Emerging functions of basophils in protective and allergic immune responses</article-title>. <source>Mucosal Immunol</source> (<year>2010</year>) <volume>3</volume>:<page-range>129&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/mi.2009.137</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roh</surname> <given-names>YS</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sutaria</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kwatra</surname> <given-names>SG</given-names>
</name>
</person-group>. <article-title>Itch: epidemiology, clinical presentation, and diagnostic workup</article-title>. <source>J Am Acad Dermatol</source> (<year>2022</year>) <volume>86</volume>:<fpage>1</fpage>&#x2013;<lpage>14</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaad.2021.07.076</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mou</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Overexpression of thymic stromal lymphopoietin in allergic rhinitis</article-title>. <source>Acta Otolaryngol</source> (<year>2009</year>) <volume>129</volume>:<fpage>297</fpage>&#x2013;<lpage>301</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/00016480802225884</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hodeib</surname> <given-names>A</given-names>
</name>
<name>
<surname>El-Samad</surname> <given-names>ZA</given-names>
</name>
<name>
<surname>Hanafy</surname> <given-names>H</given-names>
</name>
<name>
<surname>El-Latief</surname> <given-names>AA</given-names>
</name>
<name>
<surname>El-Bendary</surname> <given-names>A</given-names>
</name>
<name>
<surname>Abu-Raya</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Nerve growth factor, neuropeptides and cutaneous nerves in atopic dermatitis</article-title>. <source>Indian J Dermatol</source> (<year>2010</year>) <volume>55</volume>:<page-range>135&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4103/0019-5154.62735</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruppenstein</surname> <given-names>A</given-names>
</name>
<name>
<surname>Limberg</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Loser</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kremer</surname> <given-names>AE</given-names>
</name>
<name>
<surname>Homey</surname> <given-names>B</given-names>
</name>
<name>
<surname>Raap</surname> <given-names>U</given-names>
</name>
</person-group>. <article-title>Involvement of neuro-immune interactions in pruritus with special focus on receptor expressions</article-title>. <source>Front Med (Lausanne)</source> (<year>2021</year>) <volume>8</volume>:<elocation-id>627985</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmed.2021.627985</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orfali</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Aoki</surname> <given-names>V</given-names>
</name>
</person-group>. <article-title>Blockage of the IL-31 pathway as a potential target therapy for atopic dermatitis</article-title>. <source>Pharmaceutics</source> (<year>2023</year>) <volume>15</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/pharmaceutics15020577</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>St&#xe4;nder</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yosipovitch</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Substance p and neurokinin 1 receptor are new targets for the treatment of chronic pruritus</article-title>. <source>Br J Dermatol</source> (<year>2019</year>) <volume>181</volume>:<page-range>932&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/bjd.18025</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Critical players and therapeutic targets in chronic itch</article-title>. <source>Int J Mol Sci</source> (<year>2022</year>) <volume>23</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms23179935</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsuji</surname> <given-names>G</given-names>
</name>
<name>
<surname>Yamamura</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kawamura</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kido-Nakahara</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ito</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nakahara</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Novel therapeutic targets for the treatment of atopic dermatitis</article-title>. <source>Biomedicines</source> (<year>2023</year>) <volume>11</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/biomedicines11051303</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roblin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Yosipovitch</surname> <given-names>G</given-names>
</name>
<name>
<surname>Boyce</surname> <given-names>B</given-names>
</name>
<name>
<surname>Robinson</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sandy</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mainero</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis</article-title>. <source>Acta Derm Venereol</source> (<year>2015</year>) <volume>95</volume>:<page-range>542&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2340/00015555-2047</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanifin</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Rajka</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Diagnostic features of atopic dermatitis</article-title>. <source>Acta Derm Venereol</source> (<year>1980</year>) <volume>92</volume>:<page-range>44&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.2340/00015555924447</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyake</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ito</surname> <given-names>J</given-names>
</name>
<name>
<surname>Karasuyama</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Role of basophils in a broad spectrum of disorders</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>902494</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.902494</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Eosinophils and associated parameters in different types of skin diseases related to elevated eosinophil levels</article-title>. <source>Ann Transl Med</source> (<year>2022</year>) <volume>10</volume>:<fpage>73</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/atm-22-99</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng-Yun-Ou</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhong-Yu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Bidirectional associations between eosinophils, basophils, and lymphocytes with atopic dermatitis: a multivariable mendelian randomization study</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>1001911</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1001911</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solomon</surname> <given-names>A</given-names>
</name>
<name>
<surname>Aloe</surname> <given-names>L</given-names>
</name>
<name>
<surname>Pe&#x2019;er</surname> <given-names>J</given-names>
</name>
<name>
<surname>Frucht-Pery</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bonini</surname> <given-names>S</given-names>
</name>
<name>
<surname>Levi-Schaffer</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Nerve growth factor is preformed in and activates human peripheral blood eosinophils</article-title>. <source>J Allergy Clin Immunol</source> (<year>1998</year>) <volume>102</volume>:<page-range>454&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0091-6749(98)70135-6</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambiase</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bracci-Laudiero</surname> <given-names>L</given-names>
</name>
<name>
<surname>Bonini</surname> <given-names>S</given-names>
</name>
<name>
<surname>Starace</surname> <given-names>G</given-names>
</name>
<name>
<surname>D&#x2019;Elios</surname> <given-names>MM</given-names>
</name>
<name>
<surname>de Carli</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Human CD4+ T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors</article-title>. <source>J Allergy Clin Immunol</source> (<year>1997</year>) <volume>100</volume>:<page-range>408&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0091-6749(97)70256-2</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nilsson</surname> <given-names>G</given-names>
</name>
<name>
<surname>Forsberg-Nilsson</surname> <given-names>K</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Hallb&#xf6;&#xf6;k</surname> <given-names>F</given-names>
</name>
<name>
<surname>Nilsson</surname> <given-names>K</given-names>
</name>
<name>
<surname>Metcalfe</surname> <given-names>DD</given-names>
</name>
</person-group>. <article-title>Human mast cells express functional TrkA and are a source of nerve growth factor</article-title>. <source>Eur J Immunol</source> (<year>1997</year>) <volume>27</volume>:<page-range>2295&#x2013;301</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/eji.1830270925</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papoiu</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Nattkemper</surname> <given-names>L</given-names>
</name>
<name>
<surname>Tey</surname> <given-names>HL</given-names>
</name>
<name>
<surname>Ishiuji</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>Y-H</given-names>
</name>
<etal/>
</person-group>. <article-title>A study of serum concentrations and dermal levels of NGF in atopic dermatitis and healthy subjects</article-title>. <source>Neuropeptides</source> (<year>2011</year>) <volume>45</volume>:<page-range>417&#x2013;22</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.npep.2011.07.008</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dou</surname> <given-names>Y-C</given-names>
</name>
<name>
<surname>Hagstr&#xf6;mer</surname> <given-names>L</given-names>
</name>
<name>
<surname>Emtestam</surname> <given-names>L</given-names>
</name>
<name>
<surname>Johansson</surname> <given-names>O</given-names>
</name>
</person-group>. <article-title>Increased nerve growth factor and its receptors in atopic dermatitis: an immunohistochemical study</article-title>. <source>Arch Dermatol Res</source> (<year>2006</year>) <volume>298</volume>:<page-range>31&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00403-006-0657-1</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gray</surname> <given-names>N</given-names>
</name>
<name>
<surname>Limberg</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Br&#xe4;uer</surname> <given-names>AU</given-names>
</name>
<name>
<surname>Raap</surname> <given-names>U</given-names>
</name>
</person-group>. <article-title>Novel functions of S1P in chronic itchy and inflammatory skin diseases</article-title>. <source>J Eur Acad Dermatol Venereol</source> (<year>2022</year>) <volume>36</volume>:<page-range>365&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/jdv.17764</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Trier</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Li</surname> <given-names>F</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Chai</surname> <given-names>JN</given-names>
</name>
<etal/>
</person-group>. <article-title>A basophil-neuronal axis promotes itch</article-title>. <source>Cell</source> (<year>2021</year>) <volume>184</volume>:<fpage>422</fpage>&#x2013;<lpage>440.e17</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.12.033</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Dupilumab: advances in the off-label usage of IL4/IL13 antagonist in dermatoses</article-title>. <source>Dermatol Ther</source> (<year>2022</year>) <volume>35</volume>:<fpage>e15924</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/dth.15924</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pellefigues</surname> <given-names>C</given-names>
</name>
<name>
<surname>Naidoo</surname> <given-names>K</given-names>
</name>
<name>
<surname>Mehta</surname> <given-names>P</given-names>
</name>
<name>
<surname>Schmidt</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Jagot</surname> <given-names>F</given-names>
</name>
<name>
<surname>Roussel</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Basophils promote barrier dysfunction and resolution in the atopic skin</article-title>. <source>J Allergy Clin Immunol</source> (<year>2021</year>) <volume>148</volume>:<fpage>799</fpage>&#x2013;<lpage>812.e10</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2021.02.018</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname> <given-names>D</given-names>
</name>
<name>
<surname>Santi</surname> <given-names>CG</given-names>
</name>
<name>
<surname>Aoki</surname> <given-names>V</given-names>
</name>
<name>
<surname>Maruta</surname> <given-names>CW</given-names>
</name>
</person-group>. <article-title>Bullous pemphigoid</article-title>. <source>Bras Dermatol</source> (<year>2019</year>) <volume>94</volume>:<page-range>133&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1590/abd1806-4841.20199007</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ugajin</surname> <given-names>T</given-names>
</name>
<name>
<surname>Takahashi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Miyagishi</surname> <given-names>C</given-names>
</name>
<name>
<surname>Takayama</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yokozeki</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>A case of bullous pemphigoid associated with infiltration and activation of basophils</article-title>. <source>Br J Dermatol</source> (<year>2015</year>) <volume>173</volume>:<page-range>1095&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/bjd.13875</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kimura</surname> <given-names>R</given-names>
</name>
<name>
<surname>Sugita</surname> <given-names>K</given-names>
</name>
<name>
<surname>Horie</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yamamoto</surname> <given-names>O</given-names>
</name>
</person-group>. <article-title>Dual role of basophils in the pathogenesis of bullous pemphigoid elucidated by pathological and ultrastructural studies</article-title>. <source>Eur J Dermatol</source> (<year>2022</year>) <volume>32</volume>:<page-range>322&#x2013;33</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1684/ejd.2022.4269</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kursewicz</surname> <given-names>CD</given-names>
</name>
<name>
<surname>Fayne</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Nanda</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shah</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Nattkemper</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Pathophysiologic mechanisms of itch in bullous pemphigoid</article-title>. <source>J Am Acad Dermatol</source> (<year>2020</year>) <volume>83</volume>:<fpage>53</fpage>&#x2013;<lpage>62</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaad.2019.07.060</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimson</surname> <given-names>OG</given-names>
</name>
<name>
<surname>Giudice</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>CL</given-names>
</name>
<name>
<surname>van den Bergh</surname> <given-names>F</given-names>
</name>
<name>
<surname>Warren</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Janson</surname> <given-names>MM</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid</article-title>. <source>J Invest Dermatol</source> (<year>2003</year>) <volume>120</volume>:<page-range>784&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1046/j.1523-1747.2003.12146.x</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asbrink</surname> <given-names>E</given-names>
</name>
<name>
<surname>Hovmark</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Serum IgE levels in patients with bullous pemphigoid and its correlation to the activity of the disease and anti-basement membrane zone antibodies</article-title>. <source>Acta Derm Venereol</source> (<year>1984</year>) <volume>64</volume>:<page-range>243&#x2013;6</page-range>.</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seyed Jafari</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Gadaldi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Feldmeyer</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yawalkar</surname> <given-names>N</given-names>
</name>
<name>
<surname>Borradori</surname> <given-names>L</given-names>
</name>
<name>
<surname>Schlapbach</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Effects of omalizumab on Fc&#x3f5;RI and IgE expression in lesional skin of bullous pemphigoid</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>1919</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.01919</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuberbier</surname> <given-names>T</given-names>
</name>
<name>
<surname>Abdul Latiff</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Abuzakouk</surname> <given-names>M</given-names>
</name>
<name>
<surname>Aquilina</surname> <given-names>S</given-names>
</name>
<name>
<surname>Asero</surname> <given-names>R</given-names>
</name>
<name>
<surname>Baker</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>The international EAACI/GA&#xb2;LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria</article-title>. <source>Allergy</source> (<year>2022</year>) <volume>77</volume>:<page-range>734&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/all.15090</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grattan</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Dawn</surname> <given-names>G</given-names>
</name>
<name>
<surname>Gibbs</surname> <given-names>S</given-names>
</name>
<name>
<surname>Francis</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity</article-title>. <source>Clin Exp Allergy</source> (<year>2003</year>) <volume>33</volume>:<page-range>337&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1046/j.1365-2222.2003.01589.x</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ying</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kikuchi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Kay</surname> <given-names>AB</given-names>
</name>
<name>
<surname>Kaplan</surname> <given-names>AP</given-names>
</name>
</person-group>. <article-title>TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction</article-title>. <source>J Allergy Clin Immunol</source> (<year>2002</year>) <volume>109</volume>:<fpage>694</fpage>&#x2013;<lpage>700</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1067/mai.2002.123236</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibbs</surname> <given-names>BF</given-names>
</name>
<name>
<surname>Patsinakidis</surname> <given-names>N</given-names>
</name>
<name>
<surname>Raap</surname> <given-names>U</given-names>
</name>
</person-group>. <article-title>Role of the pruritic cytokine IL-31 in autoimmune skin diseases</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>1383</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.01383</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Chichester</surname> <given-names>KL</given-names>
</name>
<name>
<surname>Saini</surname> <given-names>SS</given-names>
</name>
</person-group>. <article-title>Association of basophil parameters with disease severity and duration in chronic spontaneous urticaria (CSU)</article-title>. <source>J Allergy Clin Immunol Pract</source> (<year>2020</year>) <volume>8</volume>:<fpage>793</fpage>&#x2013;<lpage>795.e6</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaip.2019.08.004</pub-id>
</citation>
</ref>
<ref id="B85">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baker</surname> <given-names>R</given-names>
</name>
<name>
<surname>Vasagar</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ohameje</surname> <given-names>N</given-names>
</name>
<name>
<surname>Gober</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Sterba</surname> <given-names>PM</given-names>
</name>
<etal/>
</person-group>. <article-title>Basophil histamine release activity and disease severity in chronic idiopathic urticaria</article-title>. <source>Ann Allergy Asthma Immunol</source> (<year>2008</year>) <volume>100</volume>:<page-range>244&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1081-1206(10)60449-8</pub-id>
</citation>
</ref>
<ref id="B86">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maurer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ros&#xe9;n</surname> <given-names>K</given-names>
</name>
<name>
<surname>Hsieh</surname> <given-names>H-J</given-names>
</name>
<name>
<surname>Saini</surname> <given-names>S</given-names>
</name>
<name>
<surname>Grattan</surname> <given-names>C</given-names>
</name>
<name>
<surname>Gimen&#xe9;z-Arnau</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria</article-title>. <source>N Engl J Med</source> (<year>2013</year>) <volume>368</volume>:<page-range>924&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa1215372</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poddighe</surname> <given-names>D</given-names>
</name>
<name>
<surname>Vangelista</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Effects of omalizumab on basophils: potential biomarkers in asthma and chronic spontaneous urticaria</article-title>. <source>Cell Immunol</source> (<year>2020</year>) <volume>358</volume>:<elocation-id>104215</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cellimm.2020.104215</pub-id>
</citation>
</ref>
<ref id="B88">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasagar</surname> <given-names>K</given-names>
</name>
<name>
<surname>Vonakis</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Gober</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Viksman</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gibbons</surname> <given-names>SP</given-names>
</name>
<name>
<surname>Saini</surname> <given-names>SS</given-names>
</name>
</person-group>. <article-title>Evidence of <italic>in vivo</italic> basophil activation in chronic idiopathic urticaria</article-title>. <source>Clin Exp Allergy</source> (<year>2006</year>) <volume>36</volume>:<page-range>770&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1365-2222.2006.02494.x</pub-id>
</citation>
</ref>
<ref id="B89">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsubara</surname> <given-names>D</given-names>
</name>
<name>
<surname>Yanase</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ishii</surname> <given-names>K</given-names>
</name>
<name>
<surname>Takahagi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tanaka</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ozawa</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Basophils activation of patients with chronic spontaneous urticaria in response to C5a despite failure to respond to IgE-mediated stimuli</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>994823</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.994823</pub-id>
</citation>
</ref>
<ref id="B90">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomu&#x142;ka</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wrze&#x15b;niak</surname> <given-names>M</given-names>
</name>
<name>
<surname>M&#x119;drala</surname> <given-names>W</given-names>
</name>
<name>
<surname>Panaszek</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Basophils priming in patients with chronic spontaneous urticaria</article-title>. <source>Postepy Dermatol Alergol</source> (<year>2021</year>) <volume>38</volume>:<page-range>608&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5114/ada.2021.108910</pub-id>
</citation>
</ref>
<ref id="B91">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakashima</surname> <given-names>C</given-names>
</name>
<name>
<surname>Otsuka</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kitoh</surname> <given-names>A</given-names>
</name>
<name>
<surname>Honda</surname> <given-names>T</given-names>
</name>
<name>
<surname>Egawa</surname> <given-names>G</given-names>
</name>
<name>
<surname>Nakajima</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Basophils regulate the recruitment of eosinophils in a murine model of irritant contact dermatitis</article-title>. <source>J Allergy Clin Immunol</source> (<year>2014</year>) <volume>134</volume>:<page-range>100&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2014.02.026</pub-id>
</citation>
</ref>
<ref id="B92">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dvorak</surname> <given-names>HF</given-names>
</name>
<name>
<surname>Mihm</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Basophilic leukocytes in allergic contact dermatitis</article-title>. <source>J Exp Med</source> (<year>1972</year>) <volume>135</volume>:<page-range>235&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.135.2.235</pub-id>
</citation>
</ref>
<ref id="B93">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dvorak</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Mihm</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Dvorak</surname> <given-names>HF</given-names>
</name>
</person-group>. <article-title>Degranulation of basophilic leukocytes in allergic contact dermatitis reactions in man</article-title>. <source>J Immunol</source> (<year>1976</year>) <volume>116</volume>:<page-range>687&#x2013;95</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.116.3.687</pub-id>
</citation>
</ref>
<ref id="B94">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konstantinou</surname> <given-names>GN</given-names>
</name>
<name>
<surname>Konstantinou</surname> <given-names>GN</given-names>
</name>
<name>
<surname>Koulias</surname> <given-names>C</given-names>
</name>
<name>
<surname>Petalas</surname> <given-names>K</given-names>
</name>
<name>
<surname>Makris</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Further understanding of neuro-immune interactions in allergy: implications in pathophysiology and role in disease progression</article-title>. <source>J Asthma Allergy</source> (<year>2022</year>) <volume>15</volume>:<page-range>1273&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/JAA.S282039</pub-id>
</citation>
</ref>
<ref id="B95">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Gerhold</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Bifolck-Fisher</surname> <given-names>A</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Patel</surname> <given-names>KN</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>TRPA1 is required for histamine-independent, mas-related G protein-coupled receptor-mediated itch</article-title>. <source>Nat Neurosci</source> (<year>2011</year>) <volume>14</volume>:<fpage>595</fpage>&#x2013;<lpage>602</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nn.2789</pub-id>
</citation>
</ref>
<ref id="B96">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>R</given-names>
</name>
<name>
<surname>Li</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Sputum basophils from allergic asthmatic patients do not express IL-7R&#x3b1; that is essential for TSLP signalling</article-title>. <source>Scand J Immunol</source> (<year>2023</year>) <volume>97</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/sji.13236</pub-id>
</citation>
</ref>
<ref id="B97">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salter</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Oliveria</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Nusca</surname> <given-names>G</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>SG</given-names>
</name>
<name>
<surname>Watson</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Comeau</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Thymic stromal lymphopoietin activation of basophils in patients with allergic asthma is IL-3 dependent</article-title>. <source>J Allergy Clin Immunol</source> (<year>2015</year>) <volume>136</volume>:<page-range>1636&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2015.03.039</pub-id>
</citation>
</ref>
<ref id="B98">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salabert-Le Guen</surname> <given-names>N</given-names>
</name>
<name>
<surname>H&#xe9;mont</surname> <given-names>C</given-names>
</name>
<name>
<surname>Delbove</surname> <given-names>A</given-names>
</name>
<name>
<surname>Poli</surname> <given-names>C</given-names>
</name>
<name>
<surname>Braudeau</surname> <given-names>C</given-names>
</name>
<name>
<surname>Fantou</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Thymic stromal lymphopoietin does not activate human basophils</article-title>. <source>J Allergy Clin Immunol</source> (<year>2018</year>) <volume>141</volume>:<fpage>1476</fpage>&#x2013;<lpage>1479.e6</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2017.11.012</pub-id>
</citation>
</ref>
<ref id="B99">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Th&#xe9;</surname> <given-names>L</given-names>
</name>
<name>
<surname>Batia</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Beattie</surname> <given-names>K</given-names>
</name>
<name>
<surname>Katibah</surname> <given-names>GE</given-names>
</name>
<name>
<surname>McClain</surname> <given-names>SP</given-names>
</name>
<etal/>
</person-group>. <article-title>The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch</article-title>. <source>Cell</source> (<year>2013</year>) <volume>155</volume>:<page-range>285&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2013.08.057</pub-id>
</citation>
</ref>
<ref id="B100">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>B&#xfc;rgi</surname> <given-names>B</given-names>
</name>
<name>
<surname>Otten</surname> <given-names>UH</given-names>
</name>
<name>
<surname>Ochensberger</surname> <given-names>B</given-names>
</name>
<name>
<surname>Rihs</surname> <given-names>S</given-names>
</name>
<name>
<surname>Heese</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ehrhard</surname> <given-names>PB</given-names>
</name>
<etal/>
</person-group>. <article-title>Basophil priming by neurotrophic factors. activation through the trk receptor</article-title>. <source>J Immunol</source> (<year>1996</year>) <volume>157</volume>:<page-range>5582&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.157.12.5582</pub-id>
</citation>
</ref>
<ref id="B101">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ateaque</surname> <given-names>S</given-names>
</name>
<name>
<surname>Merkouris</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wyatt</surname> <given-names>S</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>ND</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>J</given-names>
</name>
<name>
<surname>DiStefano</surname> <given-names>PS</given-names>
</name>
<etal/>
</person-group>. <article-title>Selective activation and down-regulation of trk receptors by neurotrophins in human neurons co-expressing TrkB and TrkC</article-title>. <source>J Neurochem</source> (<year>2022</year>) <volume>161</volume>:<page-range>463&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/jnc.15617</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>